LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

Search

Omnicell Inc

Aperta

SettoreSettore sanitario

46.79 0.97

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

45.74

Massimo

47.13

Metriche Chiave

By Trading Economics

Entrata

-177K

5.5M

Vendite

20M

311M

P/E

Media del settore

100.628

76.798

EPS

0.51

Margine di Profitto

1.758

Dipendenti

3,600

EBITDA

524K

31M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+1.18% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

585M

2B

Apertura precedente

45.82

Chiusura precedente

46.79

Notizie sul Sentiment di mercato

By Acuity

50%

50%

167 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Omnicell Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 dic 2025, 23:54 UTC

Azioni calde

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 dic 2025, 23:51 UTC

Utili

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 dic 2025, 23:39 UTC

I principali Market Mover

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 dic 2025, 22:57 UTC

Acquisizioni, Fusioni, Takeovers

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 dic 2025, 21:40 UTC

Utili

Nike Sales Tick Up, But China Weakness Persists

18 dic 2025, 23:45 UTC

Discorsi di Mercato

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 dic 2025, 23:37 UTC

Discorsi di Mercato
Utili

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 dic 2025, 23:36 UTC

Discorsi di Mercato

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 dic 2025, 23:03 UTC

Acquisizioni, Fusioni, Takeovers

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 dic 2025, 23:02 UTC

Acquisizioni, Fusioni, Takeovers

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 dic 2025, 23:00 UTC

Acquisizioni, Fusioni, Takeovers

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 dic 2025, 22:59 UTC

Acquisizioni, Fusioni, Takeovers

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 dic 2025, 22:58 UTC

Acquisizioni, Fusioni, Takeovers

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 dic 2025, 22:57 UTC

Acquisizioni, Fusioni, Takeovers

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 dic 2025, 22:56 UTC

Acquisizioni, Fusioni, Takeovers

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 dic 2025, 22:55 UTC

Utili

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:59 UTC

Utili

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

18 dic 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

18 dic 2025, 21:35 UTC

Utili

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 dic 2025, 21:31 UTC

Utili

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:15 UTC

Utili

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q Greater China Rev Down 17% >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q EPS 53c >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q Apparel Rev $3.91B >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q Equipment Rev $550M >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q N Amer Rev $5.63B >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q Footwear Rev $7.66B >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q Greater China Rev $1.42B >NKE

Confronto tra pari

Modifica del prezzo

Omnicell Inc Previsione

Obiettivo di Prezzo

By TipRanks

1.18% in crescita

Previsioni per 12 mesi

Media 46.33 USD  1.18%

Alto 50 USD

Basso 43 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Omnicell Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

3

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

24.23 / 30.44Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

167 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Omnicell Inc

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
help-icon Live chat